Find trials
Search tips

A Study to Evaluate the Prevalence of Mitochondrial DNA Mutations Associated with Toxicity to the Ear in the Cystic Fibrosis Population

Overview

About this study

The purpose of this study is to describe the prevalence of Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity (ear toxicity) in Cystic Fibrosis population.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults and children with a confirmed molecular diagnosis of cystic fibrosis.

Exclusion Criteria: 

  • No confirmed diagnosis of CF.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Linda Hasadsri, M.D., Ph.D.

Open for enrollment

Contact information:

Katelyn Reed B.S., M.H.S.

(507) 284-0503

Reed.Katelyn@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20506960

Mayo Clinic Footer